Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid
- PMID: 27600205
- DOI: 10.1210/jc.2016-2457
Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid
Comment in
- 
  
  Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.J Clin Endocrinol Metab. 2016 Sep;101(9):L91-2. doi: 10.1210/jc.2016-2902. J Clin Endocrinol Metab. 2016. PMID: 27600206 No abstract available.
Comment on
- 
  
  Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70. doi: 10.1210/jc.2016-1801. Epub 2016 Jun 6. J Clin Endocrinol Metab. 2016. PMID: 27270237 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
 
        